TNFSF11 and osteoporosis: To sum up, our results suggest that, from a cellular and molecular standpoint, Ori is a promising therapeutic candidate for treating bone loss illnesses such as osteoporosis and osteolysis by inhibiting osteoclast development induced by RANKL.